Imugene Ltd (ASX: IMU) Share Price and News

Ms Chong joined the Group in September 2015 from the oncology clinical development company, Genentech (a member of the Roche family), where she was a Senior Clinical Program Lead at the head office in San Francisco. She has over 25 years of experience in clinical and department development in oncology.

Mr Hopper has over 20 years of experience in the management and funding of biotechnology and healthcare public companies as chairman, chief executive officer and director in Australia and the United States. Mr Hopper's sector experience has covered several therapeutic areas with a particular emphasis on immunotherapy. He also has capital markets experience in equity and debt raisings in Australia, Asia, Europe, and the United States.

Dr Russell is a haematologist/oncologist and has over 25 years of experience and leadership in the international pharmaceutical field as a Chief Medical Officer. She has undertaken clinical development in several therapeutic areas including haematology/oncology and has had multiple new drug approvals with both FDA and European Medicines Agency. Dr Russell has experience as a director of NASDAQ listed pharmaceutical companies. She is a Member of the Risk Committee.

Dr Dupont is an industry and drug development expert with more than 20 years of experience specialising in oncology and other therapeutic areas. Dr Dupont is currently the Executive Venture Partner at Sofinnova Investments. Dr Dupont's experience includes NASDAQ listed Atara Biotherapeutics (NASDAQ: ATRA), where he oversaw all research and development, including three clinical stage programs spanning Phase 1 through to Phase 3, and numerous preclinical programs. He is a Member of the Risk Committee.

Ms Drapkin has over 25 years of experience working with private and publicly traded biotechnology and pharmaceutical companies, including building and leading finance functions, raising capital, and leading strategic financial planning. In addition to Imugene, Ms Drapkin currently serves on the board of directors at Acumen Pharmaceuticals (NASDAQ: ABOS) where she chairs the audit committee and is a member of the compensation committee and LENZ Therapeutics (NASDAQ: LENZ) where she is a member of the compensation and governance committees. Most recently, Ms Drapkin was CEO and a board member at Graphite Bio where she led the strategic alternatives process. Prior to that, Ms Drapkin was CFO at Jounce Therapeutics since its inception, playing a key role in building Jounce's financial infrastructure. She is Chair of the Risk Committee.

-

-

-

-

-